1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €30.42 (+5.26%). The median is €36.68 (+26.92%).
| Buy |
3 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
Damora Therapeutics reports quarterly loss per share of $0.39
Damora Therapeutics opened the books for the quarter ended June 30, 2026, and reported a loss per share of $0.39. In the same quarter a year earlier the company had recorded a much larger loss of $2.60 per share, so the loss has decreased significantly. » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -27.31M | 836.72% |
| EBITDA | -30.66M | 955.50% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €29.75M |
Number of shares | 1.6M |
52-week high/low | €33.08 - €1.73 |
| Dividends | No |
Beta | 1.60 |
P/E ratio | -0.25 |
PEG ratio | 0.00 |
P/B ratio | 3.63 |
P/S ratio | 0.00 |
Company profile
| Name | Damora Therapeutics |
| CEO | Jennifer A. Jarrett |
| Website | |
| Employees | 7 |
Discover assets
Shareholders of Damora Therapeutics also invest in the following assets
